This site is intended for healthcare professionals
Multiple Sclerosis (MS) Learning Zone
Declaration of sponsorship Novartis Pharma AG

High-Efficacy Therapies in MS

Declaration of sponsorship Novartis Pharma AG
Read time: 50 mins
Last updated:22nd Dec 2021
Published:22nd Dec 2021

Choosing the right treatment option at the right time is critical to managing multiple sclerosis (MS).

  • This tab summarises recent advances in high-efficacy therapies (HET) for relapsing-remitting MS [RRMS] and secondary progressive MS [SPMS])
  • Download an infographic summarising the ASCLEPIOS I and II clinical trials
  • Download an infographic showing the Phase 3 EXPAND siponimod trial and its main findings

Treatment advances for multiple sclerosis

Choosing the right treatment option at the right time is critical to managing multiple sclerosis (MS).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

ASCLEPIOS – High-efficacy therapy (HET) pivotal trial

The Novartis Pharma AG-sponsored ASCLEPIOS I and II trials are randomised, Phase 3 studies, evaluating the HET ofatumumab versus teriflunomide in adults with relapsing-multiple sclerosis (RMS).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

EXPAND – High-efficacy therapy (HET) pivotal trial

Sponsored by Novartis Pharma AG, EXPAND study is a double-blind, placebo-controlled, Phase 3 study comparing the efficacy and safety of the active HET siponimod versus placebo in secondary-progressive multiple sclerosis (SPMS).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Freedman MS, Selchen D, Prat A, Giacomini PS. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Can J Neurol Sci. 2018;45(5):489–503.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: